Saturday 31 October 2026 Export AMGN’s income statement to Excel — free account

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

466.16 5.43 +1.18%

Follow AMGN

Alert me

Market cap: $249.1B
P/E: 28.7×
Fwd P/E: 27.9×
Dividend yield: 2.13%
F-score: 7/9
Altman Z: 1.69
Beneish M: −2.27
Dividend safety: 56/100

Overview Business Profile Earnings & Analysis Segments Filings

Amgen Inc. (AMGN) revenue by segment, product and region

	Q4 FY2021	Q3 FY2021	Q2 FY2021	Q1 FY2021	Q4 FY2020	Q3 FY2020	Q2 FY2020	Q1 FY2020	Q4 FY2019	Q3 FY2019	Q2 FY2019	Q1 FY2019
Other products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
ENBREL	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Prolia	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Otezla	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
XGEVA	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other revenues	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Aranesp	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Repatha	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
KYPROLIS	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Nplate	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Vectibix	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
EVENITY	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
BLINCYTO	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
KRYSTEXXA	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
TEPEZZA	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Neulasta	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Sensipar Mimpara	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Epogen	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Product sales	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Amgen Inc. (AMGN) revenue by segment, product and region

Stockrow Weekly